David F McDermott1, Ruchit Shah2, Komal Gupte-Singh3, Javier Sabater3,4, Linlin Luo2, Marc Botteman2, Sumati Rao3, Meredith M Regan5, Michael Atkins6. 1. Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Harvard Medical School, Boston, MA, USA. dmcdermo@bidmc.harvard.edu. 2. Pharmerit International, Bethesda, MD, USA. 3. Bristol-Myers Squibb, Princeton, NJ, USA. 4. Servier, Suresnes, France. 5. Dana-Farber Cancer Institute, Boston, MA, USA. 6. Lombardi Cancer Center, Georgetown University, Washington, DC, USA.
Abstract
PURPOSE: To compare the quality-adjusted survival of nivolumab plus ipilimumab combination and nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma based on a minimum 36-month follow-up from the CheckMate 067 trial. METHODS:Overall survival was partitioned into time without symptoms of progression or toxicity (TWiST), time with treatment-related grade ≥ 3 adverse events after randomization but before progression (TOX), and time from progression until end of follow-up or death (REL). Mean quality-adjusted TWiST (Q-TWiST) was calculated by multiplying the mean time spent in each health state by a utility of 1.0 for TWiST and 0.5 for TOX and REL. Sensitivity analyses included varying utilities of TOX and REL; Q-TWiST gains at different follow-up times were calculated using EQ-5D-3L utilities from the trial. Relative Q-TWiST gain of ≥ 10% was considered clinically important. RESULTS: Compared with ipilimumab-treated patients, those who received nivolumab + ipilimumab combination had significantly longer TWiST and TOX but shorter REL; nivolumab-treated patients had significantly longer TWiST, shorter REL, and shorter but statistically nonsignificant TOX. Mean Q-TWiST was highest for nivolumab + ipilimumab (23.5 months; 95% CI 21.9-25.2), followed by nivolumab (21.8 months; 95% CI 20.2-23.4) and ipilimumab (15.3 months; 95% CI 13.9-16.6). Relative Q-TWiST gains were favorable and clinically important for nivolumab + ipilimumab combination (+ 36.81%) and nivolumab alone (+ 29.18%) versus ipilimumab alone. Relative gains increased with follow-up from 3 to 40 months for all comparisons. These gains remained consistent in magnitude and direction in the different sensitivity analyses. CONCLUSIONS:Nivolumab + ipilimumab combination and nivolumab alone resulted in a statistically significant and clinically important improvement in quality-adjusted survival compared with ipilimumab alone.
RCT Entities:
PURPOSE: To compare the quality-adjusted survival of nivolumab plus ipilimumab combination and nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma based on a minimum 36-month follow-up from the CheckMate 067 trial. METHODS: Overall survival was partitioned into time without symptoms of progression or toxicity (TWiST), time with treatment-related grade ≥ 3 adverse events after randomization but before progression (TOX), and time from progression until end of follow-up or death (REL). Mean quality-adjusted TWiST (Q-TWiST) was calculated by multiplying the mean time spent in each health state by a utility of 1.0 for TWiST and 0.5 for TOX and REL. Sensitivity analyses included varying utilities of TOX and REL; Q-TWiST gains at different follow-up times were calculated using EQ-5D-3L utilities from the trial. Relative Q-TWiST gain of ≥ 10% was considered clinically important. RESULTS: Compared with ipilimumab-treated patients, those who received nivolumab + ipilimumab combination had significantly longer TWiST and TOX but shorter REL; nivolumab-treated patients had significantly longer TWiST, shorter REL, and shorter but statistically nonsignificant TOX. Mean Q-TWiST was highest for nivolumab + ipilimumab (23.5 months; 95% CI 21.9-25.2), followed by nivolumab (21.8 months; 95% CI 20.2-23.4) and ipilimumab (15.3 months; 95% CI 13.9-16.6). Relative Q-TWiST gains were favorable and clinically important for nivolumab + ipilimumab combination (+ 36.81%) and nivolumab alone (+ 29.18%) versus ipilimumab alone. Relative gains increased with follow-up from 3 to 40 months for all comparisons. These gains remained consistent in magnitude and direction in the different sensitivity analyses. CONCLUSIONS:Nivolumab + ipilimumab combination and nivolumab alone resulted in a statistically significant and clinically important improvement in quality-adjusted survival compared with ipilimumab alone.
Authors: Caroline Robert; Georgina V Long; Benjamin Brady; Caroline Dutriaux; Michele Maio; Laurent Mortier; Jessica C Hassel; Piotr Rutkowski; Catriona McNeil; Ewa Kalinka-Warzocha; Kerry J Savage; Micaela M Hernberg; Celeste Lebbé; Julie Charles; Catalin Mihalcioiu; Vanna Chiarion-Sileni; Cornelia Mauch; Francesco Cognetti; Ana Arance; Henrik Schmidt; Dirk Schadendorf; Helen Gogas; Lotta Lundgren-Eriksson; Christine Horak; Brian Sharkey; Ian M Waxman; Victoria Atkinson; Paolo A Ascierto Journal: N Engl J Med Date: 2014-11-16 Impact factor: 91.245
Authors: Caitlyn T Solem; Youngmin Kwon; Ruchit M Shah; Abdalla Aly; Marc F Botteman Journal: Expert Rev Pharmacoecon Outcomes Res Date: 2018-02-05 Impact factor: 2.217
Authors: F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba Journal: N Engl J Med Date: 2010-06-05 Impact factor: 91.245
Authors: Joshua J Fenton; Paul R Duberstein; Richard L Kravitz; Guibo Xing; Daniel J Tancredi; Kevin Fiscella; Supriya Mohile; Ronald M Epstein Journal: J Clin Oncol Date: 2017-11-17 Impact factor: 44.544
Authors: Jacob Schachter; Antoni Ribas; Georgina V Long; Ana Arance; Jean-Jacques Grob; Laurent Mortier; Adil Daud; Matteo S Carlino; Catriona McNeil; Michal Lotem; James Larkin; Paul Lorigan; Bart Neyns; Christian Blank; Teresa M Petrella; Omid Hamid; Honghong Zhou; Scot Ebbinghaus; Nageatte Ibrahim; Caroline Robert Journal: Lancet Date: 2017-08-16 Impact factor: 79.321
Authors: James Larkin; Vanna Chiarion-Sileni; Rene Gonzalez; Jean Jacques Grob; C Lance Cowey; Christopher D Lao; Dirk Schadendorf; Reinhard Dummer; Michael Smylie; Piotr Rutkowski; Pier F Ferrucci; Andrew Hill; John Wagstaff; Matteo S Carlino; John B Haanen; Michele Maio; Ivan Marquez-Rodas; Grant A McArthur; Paolo A Ascierto; Georgina V Long; Margaret K Callahan; Michael A Postow; Kenneth Grossmann; Mario Sznol; Brigitte Dreno; Lars Bastholt; Arvin Yang; Linda M Rollin; Christine Horak; F Stephen Hodi; Jedd D Wolchok Journal: N Engl J Med Date: 2015-05-31 Impact factor: 91.245
Authors: Arthur S Zbrozek; Gary Hudes; Donna Levy; Andrew Strahs; Anna Berkenblit; Robert DeMarinis; Shreekant Parasuraman Journal: Pharmacoeconomics Date: 2010 Impact factor: 4.981
Authors: S Patil; R A Figlin; T E Hutson; M D Michaelson; S Negrier; S T Kim; X Huang; R J Motzer Journal: Br J Cancer Date: 2012-05-08 Impact factor: 7.640
Authors: Douwe Postmus; Sarah Richard; Nathalie Bere; Gert van Valkenhoef; Jayne Galinsky; Eric Low; Isabelle Moulon; Maria Mavris; Tomas Salmonsson; Beatriz Flores; Hans Hillege; Francesco Pignatti Journal: Oncologist Date: 2017-10-27
Authors: Min Huang; M Catherine Pietanza; Ayman Samkari; James Pellissier; Thomas Burke; Sheenu Chandwani; Fansen Kong; A Simon Pickard Journal: Pharmacoeconomics Date: 2019-01 Impact factor: 4.981
Authors: Kim Cocks; Marta Contente; Sarah Simpson; Michael DeRosa; Fiona C Taylor; James W Shaw Journal: Pharmacoeconomics Date: 2019-08 Impact factor: 4.981
Authors: Olivier Michielin; Michael B Atkins; Henry B Koon; Reinhard Dummer; Paolo Antonio Ascierto Journal: J Immunother Cancer Date: 2020-10 Impact factor: 13.751
Authors: Meredith M Regan; Lillian Werner; Sumati Rao; Komal Gupte-Singh; F Stephen Hodi; John M Kirkwood; Harriet M Kluger; James Larkin; Michael A Postow; Corey Ritchings; Mario Sznol; Ahmad A Tarhini; Jedd D Wolchok; Michael B Atkins; David F McDermott Journal: J Clin Oncol Date: 2019-09-09 Impact factor: 44.544